Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "Khalid, Qandeel" wg kryterium: Autor


Wyświetlanie 1-2 z 2
Tytuł:
USE OF GLUTARIC ACID TO IMPROVE THE SOLUBILITY AND DISSOLUTION PROFILE OF GLIPIZIDE THROUGH PHARMACEUTICAL COCRYSTALLIZATION
Autorzy:
Batool, Fakhra
Ahmad, Mahmood
Minhas, Muhammad U.
Khalid, Qandeel
Idrees, Hafiz A.
Khan, Fahad M.
Powiązania:
https://bibliotekanauki.pl/articles/895470.pdf
Data publikacji:
2019-02-28
Wydawca:
Polskie Towarzystwo Farmaceutyczne
Tematy:
FTIR
SEM
PXRD
thermal analysis
glipizide
glutaric acid
Opis:
The purpose of current study was to improve the solubility and dissolution profile of BCS class-II drug Glipizide using glutaric acid as a coformer via various cocrystalization techniques i.e., dry grinding, liquid assisted grinding, slurry and solvent evaporation. Fourier Transform Infrared Spectroscopy (FTIR) was performed to determine the interaction between components of glipizide-glutaric acid (GPZ-GLU) cocrystals. Powder X-ray Diffraction (PXRD) studies confirmed the crystalline nature of formulated cocrystals. Scanning Electron Microscopy (SEM) revealed cylindrical to rectangular shape of cocrystals. Flow properties of GPZ-GLU cocrystals were evaluated by micromeritics analysis. Size and surface morphology was determined by zeta sizer analysis and optical microscopy. Differential scanning calorimetry (DSC) and Thermogravimetric (TGA) analysis were performed to determine the melting points as well as thermal stability of pure components and formulated GPZ-GLU cocrystals. In-vitro drug release studies were carried out using dissolution apparatus-II. GPZ-GLU cocrystals showed higher drug release at pH 6.8 as compared to pH 1.2. However, percent drug release of optimum formulations at pH 6.8 was determined as; 24%-92.2% (F3) and 12.0%-93.5% (F7). Solubility studies revealed improved solubility as compared to pure drug in water i.e., 53 folds and 54.27 folds from F3 and F7 cocrystals, respectively. Finally it was concluded that glutaric acid has improved the solubility and dissolution profile of glipizide. However, many cocrystal formers have been reported in literature that can be used to enhance the physicochemical properties as well as bioavailability of poorly soluble drugs via cocrystalization technique.
Źródło:
Acta Poloniae Pharmaceutica - Drug Research; 2019, 76, 1; 103-114
0001-6837
2353-5288
Pojawia się w:
Acta Poloniae Pharmaceutica - Drug Research
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
DETERMINATION OF ACYCLOVIR IN RABBIT PLASMA BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC (HPLC) TECHNIQUE
Autorzy:
Malik, Nadia S.
Ahmad, Mahmood
Minhas, Muhammad U.
Khalid, Qandeel
Powiązania:
https://bibliotekanauki.pl/articles/895236.pdf
Data publikacji:
2019-06-28
Wydawca:
Polskie Towarzystwo Farmaceutyczne
Tematy:
plasma
acyclovir
Reversed phase high-performance liquid chromatography
Opis:
A rapid, sensitive and simple reversed-phase high-performance liquid chromatographic (HPLC) method has been developed and validated for the determination of acyclovir (ACV) in rabbit plasma. BDS C18 column was used to conduct analysis using ammonium dihydrogen phosphate buffer (50mM) and methanol as mobile phase (98:2), with pH adjusted to 2.5 using orthophosphoric acid. Flow rate was kept at 1 mL/min. Selective precipitation of plasma proteins were done by adding 5% perchloric acid. Precipitated plasma proteins were separated by centrifugation. ACV moves in a supernatant, which was snapped and passed through a syringe filtration assembly. Direct injection of supernatant was given into a BDS C18 column and ACV was detected at 256 nm. The limit of detection for ACV in plasma was estimated as 15ng/mL whereas the limit of quantitation was calculated as 25 ng/mL. Moreover, the developed method has been found to be selective and linear into concentration range of 25 – 2000 ng/mL. The present method could be successfully applied to samples from bioavailability and bioequivalence studies.
Źródło:
Acta Poloniae Pharmaceutica - Drug Research; 2019, 76, 3; 421-429
0001-6837
2353-5288
Pojawia się w:
Acta Poloniae Pharmaceutica - Drug Research
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-2 z 2

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies